New agents that stimulate erythropoiesis

Blood

Volumn 109, Issue 3, 2007, Pages 868-873

  Bunn, H Franklin ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; ERYTHROPOIETIN; ERYTHROPOIETIN ANTIBODY; ERYTHROPOIETIN RECEPTOR; FG 2216; FG 4592; GLYCYLGLYCYLTHREONYLTYROSYLSERYLCYSTEINYLHISTIDYLPHENYLALANYLGLYCYL PROLYLLEUCYLTHREONYLTRYPTOPHYLVALYLCYSTEINYLLYSYLPROLYLGLUTAMINYLGLYCYLGLYCINE; HEMATIDE; HEMATOLOGIC AGENT; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MACROGOL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGYLATED ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; SYNTHETIC ERYTHROPOIESIS PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANEMIA; ARTERIOVENOUS FISTULA; ARTERIOVENOUS SHUNT; CHRONIC KIDNEY DISEASE; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; ERYTHROPOIESIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN MODIFICATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME;

EID: 33846883294     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-08-019083     Document Type: Review

References (63)

1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet. 1986;2:1175-1178.
2. Eschbach JW, Ergie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of endstage renal disease with recombinant human erythropoietin. N Engl J Med. 1987;316:73-78.
3. Casadevall N, Nataf J, Viron B, et al. Pure redcell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469-475.
4. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;351:1403-1408.
5. Kaushansky K, Karplus PA. Hematopoietic growth factors: understanding functional diversity in structural terms. Blood. 1993;82:3229-3240.
6. Grodberg J, Davis KL, Sytkowski AJ. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Euro J Biochem. 1993;218:597-601.
7. Wen D, Boissel J-P, Showers M, Ruch BC, Bunn HF. Erythropoietin structure-function relationships: identification of functionally important domains. J Biol Chem. 1994;269:22839-22846.
8. Elliott S, Lorenzini T, Chang D, et al. Fine-structure epitope mapping of anti-erythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin protein structure. Blood. 1996;87:2702-2713.
9. Elliott S, Lorenzini T, Chang D, Barzilay J, Delorme E. Mapping of the active site of recombinant human erythropoietin. Blood. 1997;89:493-502.
10. Qiu H, Belanger A, Yoon HW, Bunn HF. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem. 1998;273:11173-11176.
11. Syed RS, Reid SW, Li C, et al. Efficiency of signalling through cytokine receptors depends critically on receptor orientation. Nature. 1998;395:511-516.
12. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 1999;283:987-990.
13. Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science. 1999;283:990-993.
14. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem. 2003;278:19575-19578.
15. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5:343-354.
16. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol. 2004;286:R977-R988.
17. Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest. 1999;103:691-696.
18. Rosenberger C, Mandriota S, Jurgensen JS, et al. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002;13:1721-1732.
19. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-2395.
20. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R. Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol. 2005;63:327-334.
21. Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney AP. Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology (Carlton). 2005;10:129-135.
22. Glaspy J, Vadhan-Raj S, Patel R, et al. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006;24:2290-2297.
23. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98:708-714.
24. Siddiqui MA, Keating GM. Darbepoetin alfa: a review of its use in the treatment of anaemia in patients with cancer receiving chemotherapy. Drugs. 2006;66:997-1012.
25. Stasi R, Abruzzese E, Lanzetta G, Terzoli E, Amadori S. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol. 2005;16:1921-1927.
26. Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol. 2006;133:513-519.
27. Warwood TL, Ohls RK, Wiedmeier SE, et al. Single-dose darbepoetin administration to anemic preterm neonates. J Perinatol. 2005;25:725-730.
28. Sytkowski AJ, Lunn ED, Risinger MA, Davis KL. An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties. J Biol Chem. 1999;274:24773-24778.
29. Sytkowski AJ, Lunn ED, Davis KL, Feldman L, Siekman S. Human erythropoietin dimers with markedly enhanced in vivo activity. Proc Natl Acad Sci U S A. 1998;95:1184-1188.
30. Kochendoerfer GG, Chen SY, Mao F, et al. Design and chemical synthesis of a homogeneous polymer-modified erythropoiesis protein. Science. 2003;299:884-887.
31. Jolling K, Ruixo JJ, Hemeryck A, Piotrovskij V, Greway T. Population pharmacokinetic analysis of pegylated human erythropoietin in rats. J Pharm Sci. 2004;93:3027-3038.
32. Macdougall IC. CERA (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep. 2005;4:436-440.
33. Papatheofanis FJ, McKenzie RS, Mody SH, Suruki RY, Piech CT. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Curr Med Res Opin. 2006;22:837-842.
34. Wrighton NC, Farrell FX, Chang R, et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science. 1996;273:458-463.
35. Livnah O, Stura EA, Johnson DL, et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science. 1996;273:464-471.
36. Woodburn KW, Fan Q, Leuther KK, et al. Preclinical evaluation of Hematide, a novel erythropoietin receptor agonist for the treatment of anemia caused by kidney disease [abstract]. Blood. 2004;104. Abstract no. 2094.
37. Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose escalation study in healthy volunteers. Blood. 2006;108:1830-1834.
38. Duliege A-M, Macdougall I, Duncan N, et al. Hematide, a synthetic peptide-based erythropoiesis stimulating agent (ESA) demonstrates erythropoietic activity in a phase 2 single dose escalating study in patients with chronic kidney disease (CKD) [abstract]. Blood. 2005;106. Abstract no. 3532.
39. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001;107:43-54.
40. Bernhardt WM, Campean V, Kany S, et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J Am Soc Nephrol. 2006;17:1970-1978.
41. Liu DY, Neff TB, Guenzler V, et al. Novel and beneficial pharmacodynamic properties of endogenous EPO and 'complete erythropoiesis' induced by selective HIF prolyl hydroxylase inhibitors [abstract]. J Am Soc Nephrol. 2005;16:761A.
42. Langsetmo I, Nichols B, Seeley T, et al. FG-2216 corrects anemia and improves iron utilization in a rat model of anemia of chronic disease: comparison to darbepoetin [abstract]. J Am Soc Nephrol. 2005;16:481A.
43. Günzler V, Muthukrishnan E, H.H. Neumayer KS, et al. FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease [abstract]. J Am Soc Nephrol. 2005;16:758A.
44. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614-621.
45. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.
46. Seeley TW, Langsetmo I, Stephenson R, et al. FG-2216: tumor progression studies and correction of anemia of chronic disease in xenograft models [abstract]. J Am Soc Nephrol. 2005;16:481A.
47. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993;82:3610-3615.
48. Jelkmann W, Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol. 2004;83:673-686.
49. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A. 2003;100:6741-6746.
50. Fiordaliso F, Chimenti S, Staszewsky L, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2005;102:2046-2051.
51. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A. 2004;101:14907-14912.
52. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci U S A. 1990;87:5978-5982.
53. Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A. 1994;91:3974-3978.
54. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
55. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost. 1997;78:1505-1509.
56. Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost. 1997;77:1020-1024.
57. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95:2983-2989.
58. Loo M, Beguin Y. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. Blood. 1999;93:3286-3293.
59. Yasuda Y, Musha T, Tanaka H, et al. Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice. Br J Cancer. 2001;84:836-843.
60. Arcasoy MO, Amin K, Karayal AF, et al. Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest. 2002;82:911-918.
61. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol. 2003;4:459-460.
62. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
63. Hedenus M, Vansteenkiste J, Kotasek D, Austin M, Amado RG. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol. 2005;23:6941-6948.